Ballentine Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$754K Buy
3,236
+178
+6% +$41.1K 0.01% 462
2026
Q2
$648K Sell
3,058
-1
-0% -$196 0.01% 484
2026
Q1
$600K Sell
3,059
-760
-20% -$148K 0.01% 470
2025
Q4
$663K Sell
3,819
-91
-2% -$16.6K 0.01% 416
2025
Q3
$745K Buy
3,910
+78
+2% +$13.8K 0.01% 389
2025
Q2
$688K Buy
3,832
+151
+4% +$26.2K 0.01% 394
2025
Q1
$623K Buy
3,681
+2,327
+172% +$382K 0.01% 381
2024
Q4
$204K Buy
+1,354
New +$211K ﹤0.01% 773
2017
Q3
– Sell
-5,297
Closed -$571K – 438
2017
Q2
$571K Buy
+5,297
New +$560K 0.04% 182

Other funds holding DGX

Ballentine Partners's DGX Position: Q3 2026 in Review

Ballentine Partners increased its Quest Diagnostics (DGX) stake by 5.8% in Q3 2026, buying an estimated $41.1K and bringing the position to 3,236 shares worth $754K. The position accounts for 0.01% of the portfolio, ranked #462.

Ballentine Partners first reported a position in DGX in Q2 2017 and has held it in 9 quarters since. 1,142 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Ballentine Partners held 3,236 shares of Quest Diagnostics worth $754K as of Q3 2026.
  • Ballentine Partners bought 178 Quest Diagnostics shares in Q3 2026, an estimated $41.1K.
  • Quest Diagnostics made up 0.01% of Ballentine Partners's portfolio in Q3 2026, its #462 holding.
  • Ballentine Partners first reported a position in Quest Diagnostics in Q2 2017 and has held it in 9 quarters since.
  • 1,142 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Ballentine Partners's 13F filing for Q3 2026, filed 13 Nov 2026.